Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 115

1.

Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.

Heffron R, McClelland RS, Balkus JE, Celum C, Cohen CR, Mugo N, Bukusi E, Donnell D, Lingappa J, Kiarie J, Fiedler T, Munch M, Fredricks DN, Baeten JM; Partners PrEP Study Team.

Lancet HIV. 2017 Jul 18. pii: S2352-3018(17)30110-8. doi: 10.1016/S2352-3018(17)30110-8. [Epub ahead of print]

PMID:
28732773
2.

The Effect of Oral Pre-Exposure Prophylaxis on the Progression of HIV-1 Seroconversion.

Donnell D, Ramos E, Celum C, Baeten J, Dragavon J, Tappero J, Lingappa JR, Ronald A, Fife K, Coombs RW; Partners PrEP Study Team.

AIDS. 2017 Jul 7. doi: 10.1097/QAD.0000000000001577. [Epub ahead of print]

PMID:
28692542
3.

Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients: A Randomized Clinical Trial (HPTN 065).

El-Sadr WM, Donnell D, Beauchamp G, Hall HI, Torian LV, Zingman B, Lum G, Kharfen M, Elion R, Leider J, Gordin FM, Elharrar V, Burns D, Zerbe A, Gamble T, Branson B; HPTN 065 Study Team.

JAMA Intern Med. 2017 Jun 19. doi: 10.1001/jamainternmed.2017.2158. [Epub ahead of print]

PMID:
28628702
4.

Design of the HPTN 065 (TLC-Plus) study: A study to evaluate the feasibility of an enhanced test, link-to-care, plus treat approach for HIV prevention in the United States.

Gamble T, Branson B, Donnell D, Hall HI, King G, Cutler B, Hader S, Burns D, Leider J, Wood AF, G Volpp K, Buchacz K, El-Sadr WM; HPTN 065 Study Team.

Clin Trials. 2017 Jun 1:1740774517711682. doi: 10.1177/1740774517711682. [Epub ahead of print]

PMID:
28627929
5.

A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial.

Hayes R, Floyd S, Schaap A, Shanaube K, Bock P, Sabapathy K, Griffith S, Donnell D, Piwowar-Manning E, El-Sadr W, Beyers N, Ayles H, Fidler S; HPTN 071 (PopART) Study Team.

PLoS Med. 2017 May 2;14(5):e1002292. doi: 10.1371/journal.pmed.1002292. eCollection 2017 May.

6.

Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.

Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B, Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K, Hakim J, Kumarasamy N, Campbell TB; ACTG PEARLS/A5175 Team.

J Infect Dis. 2017 Mar 15;215(6):907-910. doi: 10.1093/infdis/jix029.

PMID:
28453835
7.

Correction for Lund et al., HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.

Lund JM, Broliden K, Pyra MN, Thomas KK, Donnell D, Irungu E, Muwonge TR, Mugo N, Manohar M, Jansson M, Mackelprang R, Marzinke MA, Baeten JM, Lingappa JR.

J Virol. 2017 Jan 18;91(3). pii: e02074-16. doi: 10.1128/JVI.02074-16. Print 2017 Feb 1. No abstract available.

8.

Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study.

Justman J, Reed JB, Bicego G, Donnell D, Li K, Bock N, Koler A, Philip NM, Mlambo CK, Parekh BS, Duong YT, Ellenberger DL, El-Sadr WM, Nkambule R.

Lancet HIV. 2017 Feb;4(2):e83-e92. doi: 10.1016/S2352-3018(16)30190-4. Epub 2016 Nov 16.

9.

Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence.

Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, Hammer SM, Gilbert PB, Donnell DJ.

J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):606-608.

PMID:
27846073
10.

Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043).

Fogel JM, Clarke W, Kulich M, Piwowar-Manning E, Breaud A, Olson MT, Marzinke MA, Laeyendecker O, Fiamma A, Donnell D, Mbwambo JK, Richter L, Gray G, Sweat M, Coates TJ, Eshleman SH.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):158-165. doi: 10.1097/QAI.0000000000001229.

PMID:
27828875
11.

Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.

Kourtis AP, Wiener J, King CC, Heffron R, Mugo NR, Nanda K, Pyra M, Donnell D, Celum C, Lingappa JR, Baeten JM; Partners in Prevention HSVHIV Transmission Study and Partners PrEP Study Teams.

J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):38-43.

12.

Changing Clinician Practices and Attitudes Regarding the Use of Antiretroviral Therapy for HIV Treatment and Prevention.

Buchacz K, Farrior J, Beauchamp G, McKinstry L, Kurth AE, Zingman BS, Gordin FM, Donnell D, Mayer KH, El-Sadr WM, Branson B; HPTN 065 Study Team.

J Int Assoc Provid AIDS Care. 2017 Jan/Feb;16(1):81-90. doi: 10.1177/2325957416671410. Epub 2016 Oct 5.

PMID:
27708115
13.

Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception.

Heffron R, Parikh UM, Penrose KJ, Mugo N, Donnell D, Celum C, Mellors JW, Baeten JM; Partners PrEP Study Team.

AIDS Behav. 2017 Jul;21(7):2173-2179. doi: 10.1007/s10461-016-1563-y.

PMID:
27699594
14.

HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.

Lund JM, Broliden K, Pyra MN, Thomas KK, Donnell D, Irungu E, Muwonge TR, Mugo N, Manohar M, Jansson M, Mackelprang R, Marzinke MA, Baeten JM, Lingappa JR.

J Virol. 2016 Oct 14;90(21):9855-9861. Print 2016 Nov 1. Erratum in: J Virol. 2017 Jan 18;91(3):.

15.

Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.

Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, Asiimwe S, Haberer JE, Morton J, Ngure K, Bulya N, Odoyo J, Tindimwebwa E, Hendrix C, Marzinke MA, Ware NC, Wyatt MA, Morrison S, Haugen H, Mujugira A, Donnell D, Celum C; Partners Demonstration Project Team.

PLoS Med. 2016 Aug 23;13(8):e1002099. doi: 10.1371/journal.pmed.1002099. eCollection 2016 Aug.

16.

Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.

Mugwanya K, Baeten J, Celum C, Donnell D, Nickolas T, Mugo N, Branch A, Tappero J, Kiarie J, Ronald A, Yin M, Wyatt C; Partners PrEP Study Team.

J Infect Dis. 2016 Oct 1;214(7):1050-7. doi: 10.1093/infdis/jiw125. Epub 2016 Mar 29.

PMID:
27029778
17.

PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials.

Dimitrov DT, M√Ęsse BR, Donnell D.

J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):444-51. doi: 10.1097/QAI.0000000000000993.

PMID:
26990823
18.

Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.

Mugwanya KK, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A, Baeten JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):374-80. doi: 10.1097/QAI.0000000000000868.

19.

Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.

Weis JF, Baeten JM, McCoy CO, Warth C, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Mugo N, Matsen FA IV, Celum C, Lehman DA; Partners PrEP Study Team.

AIDS. 2016 Jan 2;30(1):31-5. doi: 10.1097/QAD.0000000000000915.

20.

Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection.

Pattacini L, Baeten JM, Thomas KK, Fluharty TR, Murnane PM, Donnell D, Bukusi E, Ronald A, Mugo N, Lingappa JR, Celum C, McElrath MJ, Lund JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):119-28. doi: 10.1097/QAI.0000000000000919.

Supplemental Content

Loading ...
Support Center